Abstract: The present invention relates to compounds which specifically inhibit bacterial DNA Gyrase and can be used for the treatment of respiratory tract infections.
Abstract: The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.
Type:
Grant
Filed:
September 18, 2012
Date of Patent:
August 25, 2015
Assignee:
VITAS PHARMA RESEARCH PRIVATE LIMITED
Inventors:
Radha Rangarajan, Rajinder Kumar, B V Prabhakar, P Chandrasekhar, P Mallikarjuna, Ankita Banerjee